High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户:cartman8148
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.Background.Iron is essential for the formation of hemoglobin.During long-term treatment with human recombinant erythropoietin (rhEPO), the majority of end-stage renal disease (ESRD) patients will not respond adequately to rhEPO unless substituted with intravenous iron.However, concern exists about possible detrimental effects of parenteral iron on cellular host defense and iron-mediated increments of oxidative stress.
其他文献
Iron deficiency is an important cause of anemia in patients with chronic kidney disease (CKD), but intravenous iron is infrequently used among patients who are not on dialysis.Ferumoxytol is a novel i
会议
Background: Serum ferritin, frequently used as a marker of iron status in individuals with chronic kidney disease, is also an inflammatory marker.The concurrent combination of high serum ferritin and
会议
Background and objectives: As well as being a marker of body iron stores, serum ferritin (sFerritin) has also been shown to be a marker of inflammation in hemodialysis (HD) patients.The aim of this st
会议
铁是合成血红蛋白的基本原料.流行病学及临床的研究证实在慢性肾脏病(CKD)贫血患者中常常存在一定程度的铁缺乏[1,2],铁缺乏也是导致红细胞刺激剂(ESA)治疗反应差的主要原因,予以充足的铁补充 ,不仅可以明显改善贫血,还可以减少ESA的使用剂量,甚至在未使用ESA的情况下也能改善贫血[3,4].因此对于CKD贫血患者需常规进行铁状态的评价,搜寻导致铁缺乏的原因.并根据患者的铁状态予以相应的铁剂补
会议
Introduction Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree
Introduction Despite major recent therapeutic improvements, septic shock remains a leading cause of mortality in intensive care patients [1].For more than a decade, it has been advocated [2,3] that th
Sodium ferric gluconate complex in hemodialysis patients:Adverse reactions compared to placebo and iron dextran.Background.Parenteral iron is often required by hemodialysis patients to maintain adequa
The Dialysis Patients Response to Ⅳ Iron with Elevated Ferritin (DRIVE) study demonstrated the efficacy of intravenous ferric gluconate to improve hemoglobin levels in anemic hemodialysis patients who
会议
Background.Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease.Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans
Bacterial sepsis is the second leading cause of death among hemodialysis (HD) patients.Iron overload and intravenous iron therapy are linked to bacterial infection.This study examined iron stores, int
会议